-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The disease caused by Marburg virus has a rapid onset, accompanied by severe headaches and severe discomfort.
A new study conducted by Galveston National Laboratory (UTMB) at the University of Texas at Galveston shows that the combination of monoclonal antibodies and the antiviral drug Remdesivir has great benefits in the treatment of advanced Marburg virus infections .
A new study conducted by Galveston National Laboratory (UTMB) at the University of Texas at Galveston shows that the combination of monoclonal antibodies and the antiviral drug Remdesivir has great benefits in the treatment of advanced Marburg virus infections .
immunity
The UTMB team and Gilead have been developing monoclonal antibody (mAb) treatments to treat extremely dangerous viral infections like Marburg virus and Ebola virus.
Original source:
Original source:href="" target="_blank" rel="noopener">leave a message here